跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
COMIRNATY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
COMIRNATY
Authorized
STANDARD
COMIRNATY
BioNTech Manufacturing GmbH
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
89192ae01302432e
Company
BioNTech Manufacturing GmbH
Type
Standard
Approval Details
Approval Id
89192ae01302432e
Drug Approval Canada Name
COMIRNATY
Product Name
COMIRNATY
Status
Marketed
Status Date
2024-09-30
Original Market Date
2023-10-10
Din
02541823
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BN01 COVID-19, RNA-BASED VACCINE
Atc Name
j 07 bn 01
Aig Number
0166244001
Company Name
BioNTech Manufacturing GmbH
Company Address
An Der Goldgrube 12, Mainz, Rheinland-Pfalz, Germany, 55131
Company Detail Path
/organization/biontech-manufacturing-gmbh
Company Information
Pharmaceutical Company Name
BioNTech Manufacturing GmbH
Country Name
Germany
Province Name
rheinland-pfalz
Active Ingredients
*SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER
30 MCG / 0.3 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
89192ae01302432e
Type
Standard
Back to Health Canada Approvals